Enoximone

Enoximone

File:Enoximone.svg
Systematic (IUPAC) name
4-methyl-5-{[4-(methylsulfanyl)phenyl]carbonyl}-2,3-dihydro-1H-imidazol-2-one
Clinical data
AHFS/Drugs.com	International Drug Names
Legal status	UK: POM (Prescription only)
Routes of administration	Intravenous
Pharmacokinetic data
Bioavailability	50% (oral)
Protein binding	85%
Metabolism	Hepatic oxidation
Biological half-life	4 to 10 hours
Excretion	Renal (60 to 70%)
Identifiers
CAS Number	77671-31-9 Y
ATC code	C01CE03 (WHO)
PubChem	CID: 53708
DrugBank	DB04880 Y
ChemSpider	48492 Y
UNII	C7Z4ITI7L7 Y
KEGG	D04004 Y
ChEMBL	CHEMBL249856 Y
Chemical data
Formula	C12H12N2O2S
Molecular mass	248.302 g/mol
SMILES O=C(/C1=C(/NC(=O)N1)C)c2ccc(SC)cc2
InChI InChI=1S/C12H12N2O2S/c1-7-10(14-12(16)13-7)11(15)8-3-5-9(17-2)6-4-8/h3-6H,1-2H3,(H2,13,14,16) Y Key:ZJKNESGOIKRXQY-UHFFFAOYSA-N Y
(verify)

Enoximone (INN, trade name Perfan) is an imidazole phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure and is selective for phosphodiesterase 3.